Patents Examined by Charanjit Aulakh
  • Protein tyrosine phosphatase inhibitors
    Patent number: 11634417
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam W. Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren T. McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina E. Wong
  • Method of controlling depression in subjects treated for opioid dependence
    Patent number: 11617746
    Abstract: The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode. The method comprises treating the subject with an opioid agonist whilst managing their depression or depressive disorder using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 4, 2023
    Assignee: OREXO AB
    Inventor: Michael John Sumner
  • Combination therapy for the treatment of triple-negative breast cancer
    Patent number: 11607405
    Abstract: The invention provides methods for treating triple negative breast cancer (TNBC), by co-administration of a BET bromodomain inhibitor selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof, and a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be a PARP inhibitor, such as, e.g., talazoparib, olaparib or veliparib.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 21, 2023
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Eric Campeau, Laura Tsujikawa, Sanjay Lakhotia
  • Photoactive compound
    Patent number: 11600785
    Abstract: A compound of formula (I): EAG-EDG-EAG?? (I) wherein each EAG is an electron accepting group; and EDG is an electron-donating group of formula (IIa): The compound of formula (I) may be used in a photosensitive layer of an organic photodetector wherein the photosensitive layer comprises the compound of formula (I) and an electron donor. A photosensor may comprise the organic photodetector and a light source, e.g. a near infra-red light source.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: March 7, 2023
    Assignee: Sumitomo Chemical Company Limited
    Inventor: Kiran Kamtekar
  • JAK1 pathway inhibitors for the treatment of gastrointestinal disease
    Patent number: 11596632
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 7, 2023
    Assignee: Incyte Corporation
    Inventors: Krishnaswamy Yeleswaram, Paul Smith, Gregory F. Hollis
  • IRAK degraders and uses thereof
    Patent number: 11591332
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: February 28, 2023
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Matthew M. Weiss, Xiaozhang Zheng, Xiao Zhu
  • Phosphor-tetrazine compound and use thereof
    Patent number: 11584749
    Abstract: The present invention relates to a novel phosphor-tetrazine and a use thereof and, more particularly, provides a novel compound having high fluorescence amplification efficiency in various wavelength ranges by using a compound having a novel core skeleton called tert-butyl (3-(7-(6-methyl-1,2,4,5-tetrazin-3-yl)-3-oxo-9-phenyl-1H-pyrrolo[3,4-b]indolizin-2(3H)-yl)propyl)carbamate.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 21, 2023
    Assignees: Spark Biopharma, Inc., Seoul National University R&DB Foundation
    Inventors: Seung Bum Park, Young Jun Lee
  • Spirocyclic compounds
    Patent number: 11584748
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 21, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • MASP-2 inhibitors and methods of use
    Patent number: 11584714
    Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: February 21, 2023
    Assignee: OMEROS CORPORATION
    Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
  • Organic luminescent material containing 6-silyl-substituted isoquinoline ligand
    Patent number: 11581498
    Abstract: An organic light-emitting material contains a 6-silyl-substituted isoquinoline ligand. The organic light-emitting material is a metal complex containing a 6-silyl-substituted isoquinoline ligand and may be used as a light-emitting material in a light-emitting layer of an organic electroluminescent device. These new complexes can provide redder and saturated emission and meanwhile demonstrate a significantly improved lifetime and efficient and excellent device performance. Further disclosed are an electroluminescent device and a compound formulation including the metal complex.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: February 14, 2023
    Assignee: BEIJING SUMMER SPROUT TECHNOLOGY CO., LTD.
    Inventors: Nannan Lu, Zhihong Dai, Cuifang Zhang, Qi Zhang, Chi Yuen Raymond Kwong, Chuanjun Xia
  • Inhibiting mutant IDH-1
    Patent number: 11576906
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: February 14, 2023
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • Heterocyclic RIP1 inhibitory compounds
    Patent number: 11578078
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 14, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11578072
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 14, 2023
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Isoquinolin-3-yl carboxamides and preparation and use thereof
    Patent number: 11548872
    Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 10, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
  • Compositions and methods for treating synucleinopathies
    Patent number: 11547700
    Abstract: The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: January 10, 2023
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Synthesis of tipifarnib
    Patent number: 11542244
    Abstract: Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: January 3, 2023
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Pingda Ren, Xiaohu Deng, Wanping Mai
  • Fasoracetam crystalline forms
    Patent number: 11535604
    Abstract: The disclosure is directed to crystalline forms and mixtures thereof of R-fasoracetam. Such crystalline forms include Form II monohydrate R-fasoracetam and the anhydrate form of R-fasoracetam. The disclosure further includes mixtures of the anhydrate form of R-fasoracetam together with one or more of Form I monohydrate R-fasoracetam and Form II monohydrate R-fasoracetam.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 27, 2022
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Tom Leyssens, Bram Harmsen
  • Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
    Patent number: 11534431
    Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: December 27, 2022
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: Jing Song, Lai Wang, Kang Li, Tong Zhang, Lusong Luo, Min Wei, Zhiyu Tang, Guoliang Zhang, Changyou Zhou
  • Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
    Patent number: 11524960
    Abstract: The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 13, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventors: Zenon D. Konteatis, Mingzong Li, Peng Liu, Matthew Medeiros, Samuel K. Reznik, Zhihua Sui, Jeremy M. Travins, Janeta Popovici-Muller, Shubao Zhou, Guangning Ma
  • Indole and azaindole inhibitors of pad enzymes
    Patent number: 11524959
    Abstract: The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: December 13, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Anurag S. Srivastava, Robert J. Cherney, Khehyong Ngu